GROUPE HOSPITALIER UNIVERSITAIRE PARIS PSYCHIATRIE ET NEUROSCIENCES

Their core work

This is a major Parisian university hospital group specializing in psychiatry and neurosciences. Within H2020, they contributed clinical expertise in stroke treatment and brain recovery, participating in multinational trials for regenerative stem cell therapies and neuroprotective interventions. Their role centers on clinical validation — providing patient cohorts, neuroimaging data, and clinical endpoints for experimental stroke treatments developed across European consortia.

What they specialise in

How they've shifted over time

Their early H2020 work (2015-2016) focused on regenerative medicine — using stem cell therapies and advanced MRI to promote brain repair after stroke. By 2017, their focus shifted toward acute neuroprotection, investigating oxygen-based interventions and biomarkers for stroke patients. This trajectory moves from experimental regenerative treatments toward more immediately actionable clinical interventions in stroke care.

Moving from experimental regenerative approaches toward clinically translatable neuroprotective stroke interventions, suggesting readiness for later-stage clinical trials and biomarker validation studies.

How they like to work

They exclusively join projects led by others — never coordinating — and contributed once as a third party, indicating a specialist clinical site role rather than a project leadership function. With 51 unique partners across 11 countries from just 3 projects, they operate in large multinational consortia typical of clinical trial networks. This profile suggests they are a trusted clinical partner valued for patient access and neuroscience expertise, not a project initiator.

Despite only 3 projects, they have worked with 51 distinct partners across 11 countries, reflecting the large consortium structure of EU clinical trial projects. Their network is broadly European with no single dominant geographic cluster.

What sets them apart

As a dedicated psychiatry and neurosciences hospital in Paris, they offer direct access to stroke patient cohorts and specialized neuroimaging infrastructure — resources that are difficult for non-clinical partners to replicate. Their dual experience in both regenerative and neuroprotective stroke research gives them unusually broad clinical trial competence across the stroke treatment pipeline. For consortium builders, they represent a credible French clinical site with proven ability to deliver within large EU research collaborations.

Highlights from their portfolio

• PROOF
  Received the bulk of their EU funding (EUR 103,347) and ran until 2023, making it their longest and most substantial H2020 engagement in stroke neuroprotection.
• RESSTORE
  A pioneering European trial on stem cell therapy for stroke recovery, positioning the hospital at the intersection of regenerative medicine and neurology.